Trial Profile
The EQUAL study: A randomised trial to study the EQUivalence of three monthly intravitreal injections and additional injections as needed of bevacizumab (Avastin) and ranibizumab (Lucentis) on visual acuity in patients with exudative age-related macular degeneration.
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 May 2009
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Ranibizumab (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- Acronyms EQUAL
- 12 May 2009 New trial record